查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813971

類風濕性關節炎藥物市場規模、佔有率和趨勢分析報告：按分子、銷售管道、地區和細分市場預測，2025-2033 年

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

類風濕性關節炎治療市場摘要

預計 2024 年全球類風濕性關節炎治療市場價值為 257.6 億美元，到 2033 年將達到 414.2 億美元，2025 年至 2033 年的複合年成長率為 5.56%。

類風濕性關節炎(RA) 創新療法的引入在推動市場成長方面發揮關鍵作用。

安進公司、輝瑞公司、基因泰克公司和諾華等主要企業相繼推出賽妥珠單抗、Hyrimoz、Amgevita、Erelzi、Absola和利妥昔單抗等新型生物相似藥，大大重塑了類風濕性關節炎（RA）治療的格局。例如，2024年5月，勃林格殷格翰公司宣布美國食品藥物管理局（FDA）核准Rituximab。同樣在2024年5月，勃林格殷格翰宣布，美國食品藥物管理局（克隆氏症了Humira的生物相似潰瘍性大腸炎 （阿達木單抗-adbm）的僵直性脊椎炎，用於治療多種慢性發炎性疾病，包括斑塊型乾癬、克隆氏乾癬性關節炎、潰瘍性結腸炎、牛皮癬、乾癬關節炎、膿皰性Adalimumab核准、中度至重度斑塊狀乾癬、非感染性葡萄膜炎。

同樣，2023 年 1 月，諾華公司獲得了歐洲藥品管理局人用藥品委員會 (CHMP) 對山德士 Hylimoz（Adalimumab）無檸檬酸鹽高濃度製劑 (HCF) 的上市核准。此項核准將批准範圍擴大到參考藥物的所有適應症，包括 RA、葡萄膜炎、潰瘍性大腸炎和斑塊型乾癬。這些新一代生物生技藥品和生物相似藥旨在作用於導致關節疼痛和發炎的特定免疫系統分子和受體，從而改善治療效果。對此類有針對性和高效治療的需求不斷成長，預計將進一步推動 RA生物製藥的進步。

近年來，類風濕性關節炎（RA）的治療策略已轉向能夠誘導疾病緩解的新型分子。這項進展源於對類風濕性關節炎（RA）潛在機制的深入了解，並促進了生物目標和合成的緩解疾病的抗風濕藥物 (DMARD) 的開發。雖然小分子 DMARD、皮質類固醇、鎮痛藥和非類固醇消炎劑(NSAID) 仍然是第一線治療方法，但它們的主要目的是減緩疾病進展或抑制炎症，而非治癒 RA。此外，這些藥物可能出現嚴重的副作用，包括胃腸道潰瘍、免疫抑制、骨質疏鬆、噁心、細胞流失、疲勞、肝損傷、牛皮癬以及感染疾病風險增加。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章類類風濕性關節炎關節炎藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章類風濕性關節炎藥物市場：分子業務分析

  • 2024 年及 2033 年分子市場佔有率
  • 分子細分儀表板
  • 2021 年至 2033 年按分子分類的市場規模、預測與趨勢分析
  • 製藥
  • 生物製藥

第5章類風濕性關節炎治療市場：銷售管道業務分析

  • 2024年及2033年銷售管道市場佔有率
  • 銷售管道細分儀表板
  • 2021-2033 年按銷售管道分類的市場規模、預測與趨勢分析
  • 處方箋
  • 非處方藥

第6章類風濕性關節炎治療市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場儀表板
  • 2021-2033 年市場規模與預測趨勢分析：
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AbbVie, Inc.
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • UCB SA
    • Johnson &Johnson Services, Inc.
    • Amgen, Inc.
    • Lilly（Eli Lilly and Company）
Product Code: GVR-2-68038-313-3

Rheumatoid Arthritis Therapeutics Market Summary

The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.

The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company's interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.

In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sandoz's citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.

In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA's underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.

Global Rheumatoid Arthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

  • Molecule Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • Anti-IL6 biologics
    • Biosimilars
    • CD20 antigen
    • TNF-a antagonists
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription
  • Over-the-Counter (OTC)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis

  • 4.1. Molecule Market Share, 2024 & 2033
  • 4.2. Molecule Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
  • 4.4. Pharmaceuticals
    • 4.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.4.2. NSAIDs
      • 4.4.2.1. NSAIDs Market, 2021 - 2033 (USD Million)
    • 4.4.3. Analgesics
      • 4.4.3.1. Analgesics Market, 2021 - 2033 (USD Million)
    • 4.4.4. DMARDs
      • 4.4.4.1. DMARDs Market, 2021 - 2033 (USD Million)
    • 4.4.5. Glucocorticoids
      • 4.4.5.1. Glucocorticoids Market, 2021 - 2033 (USD Million)
  • 4.5. Biopharmaceuticals
    • 4.5.1. Biopharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market, 2021 - 2033 (USD Million)
      • 4.5.2.2. TNF-a antagonists
        • 4.5.2.2.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)
      • 4.5.2.3. T-cell inhibitors
        • 4.5.2.3.1. T-cell inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.4. CD20 antigen
        • 4.5.2.4.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.2.5. JAK inhibitors
        • 4.5.2.5.1. JAK inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.6. Anti-IL6 biologics
        • 4.5.2.6.1. Anti-IL6 biologics Market, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilars
      • 4.5.3.1. Biosimilars Market, 2021 - 2033 (USD Million)
      • 4.5.3.2. CD20 antigen
        • 4.5.3.2.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.3.3. TNF-a antagonists
        • 4.5.3.3.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis

  • 5.1. Sales Channel Market Share, 2024 & 2033
  • 5.2. Sales Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription Market, 2021 - 2033 (USD Million)
  • 5.5. Over-the-Counter (OTC)
    • 5.5.1. Over-the-Counter (OTC) Market, 2021 - 2033 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Molecule Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Molecule Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Molecule Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Regeneron Pharmaceuticals Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Molecule Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Molecule Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Molecule Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. F. Hoffmann-La Roche Ltd.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Molecule Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. UCB S.A.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Molecule Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Johnson & Johnson Services, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Molecule Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Amgen, Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Molecule Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Lilly (Eli Lilly and Company)
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Molecule Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 4 Global rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 5 North America rheumatoid arthritis therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 6 North America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 7 North America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 8 U.S. rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 9 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 10 Canada rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 11 Canada rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 13 Mexico rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 14 Europe rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 15 Europe rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 16 Europe rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 17 UK rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 18 UK rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 19 Germany rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 20 Germany rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 21 France rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 22 France rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 23 Italy rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 24 Italy rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 25 Spain rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 26 Spain rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 27 Norway rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 28 Norway rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 29 Sweden rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 30 Sweden rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 31 Denmark rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 32 Denmark rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 36 Japan rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 37 Japan rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 38 China rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 39 China rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 40 India rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 41 India rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 42 Australia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 43 Australia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 44 South Korea rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 45 South Korea rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 46 Thailand rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 47 Thailand rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 48 Latin America rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Latin America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 50 Latin America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 51 Brazil rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 52 Brazil rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 53 Argentina rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 54 Argentina rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 55 Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 58 South Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 59 South Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 62 UAE rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 63 UAE rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 64 Kuwait rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 65 Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rheumatoid arthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and molecule outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rheumatoid arthritis therapeutics market dynamics
  • Fig. 12 Rheumatoid arthritis therapeutics market: Porter's five forces analysis
  • Fig. 13 Rheumatoid arthritis therapeutics market: PESTLE analysis
  • Fig. 14 Molecule market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 Biopharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 T-cell inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 JAK inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Anti-IL6 biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Biosimilars market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Pharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 NSAIDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Analgesics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 DMARDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Glucocorticoids market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
  • Fig. 31 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
  • Fig. 32 Prescription market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Over-the-Counter (OTC) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Rheumatoid arthritis therapeutics market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 US country dynamics
  • Fig. 38 US rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Latin America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 MEA rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework